Non-Hodgkin lymphoma (NHL) is a common lymphoid hematological malignancy, the treatment and prognosis of NHL have always been the focus of clinical attention. Chemotherapy is the main first-line treatment, but there is still no effective treatment for patients with poor response to chemotherapy, recurrence or progression within a short period of time after treatment, and new and effective drugs need to be developed clinically. As the only clinically validated oral selective inhibitor of nuclear export (SINE), Selinexor has been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma and multiple myeloma, clinical attempts are being made to apply it to the treatment of other hematological malignancies.This article reviews the anti-tumor mechanism of Selinexor and the latest research progress in its application in NHL, and provides ideas for a more diverse, standardized and effective applications of Selinexor in NHL.
题目: Selinexor治疗非霍奇金淋巴瘤的最新研究进展.
摘要: 非霍奇金淋巴瘤（NHL）是一种常见的淋巴造血系统恶性肿瘤，NHL的治疗和预后一直是临床关注的重点。其一线治疗以化疗为主，但对化疗反应不佳、治疗后短期内复发或进展的患者尚缺乏有效的治疗手段，临床上需要研发新型有效药物。作为目前唯一一款经过临床验证的口服型选择性核输出抑制剂（selective inhibitor of nuclear export，SINE），Selinexor已获批用于治疗复发性/难治性弥漫性大B细胞淋巴瘤和多发性骨髓瘤，临床正尝试将其应用于治疗其他血液系统恶性肿瘤。现就Selinexor抗肿瘤的作用机制和在 NHL 中应用的最新研究进展作一综述，为Selinexor在 NHL 中更加多样、规范、有效的应用提供思路.
Keywords: XPO1; mechanism; non-Hodgkin lymphoma; selinexor.